REGENERON PHARMACEUTICALS (REGN) Stock Income Statement
NASDAQ:REGN - Nasdaq - US75886F1075 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 14.09B | 14.20B | 13.12B | 12.17B | 16.07B | |||
| Cost Of Goods | 1.87B | 1.84B | 1.71B | 1.56B | 2.44B | |||
| Gross Profit | 12.21B | 12.36B | 11.40B | 10.61B | 13.63B | |||
| Operating Expenses | 8.15B | 8.14B | 7.07B | 5.62B | 4.69B | |||
| Research and Development | 5.06B | 5.13B | 4.44B | 3.59B | 2.91B | |||
| Selling, General, and Administrative Expenses | 3.05B | 2.95B | 2.63B | 2.12B | 1.82B | |||
| Operating Income | 4.06B | 4.22B | 4.34B | 4.99B | 8.95B | |||
| Interest Income/Expense | 1.13B | 773.40M | 172.20M | -20.00M | 329.00M | |||
| Other Income/Expense | 24.50M | 15.80M | -20.00M | 140.00M | 50.00M | |||
| Non Recurring Items | -232.50M | -227.30M | -288.40M | -255.00M | N/A | |||
| Income Before Taxes | 4.98B | 4.78B | 4.20B | 4.86B | 9.33B | |||
| Income Tax | 484.90M | 367.30M | 245.70M | 520.00M | 1.25B | |||
| Net Income | 4.50B | 4.41B | 3.95B | 4.34B | 8.07B | |||
| EBITDA | 4.56B | 4.70B | 4.76B | 5.34B | 9.23B | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | 39.30 | 38.34 | 34.77 | 38.05 | 72.09 | |||
| Non GAAP EPS | 44.31 | 45.64 | 43.78 | 42.40 | 71.38 | |||
| Statistics | ||||||||
| Gross Profit Margin | 86.69% | 87.01% | 86.94% | 87.18% | 84.83% | |||
| Profit Margin | 31.94% | 31.07% | 30.14% | 35.64% | 50.24% | |||
| Operating Profit Margin | 28.85% | 29.70% | 33.05% | 41.03% | 55.67% | |||
All data in USD